Cart
sales@molnova.com
BI-4020
CAS No. 2664214-60-0
BI-4020 ( —— )
Catalog No. M26071 CAS No. 2664214-60-0
BI-4020 is a fourth-generation, non-covalent, and orally active inhibitor of EGFR tyrosine kinase.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 627 | In Stock |
|
| 10MG | 896 | In Stock |
|
| 25MG | 1341 | In Stock |
|
| 50MG | 1791 | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameBI-4020
-
NoteResearch use only, not for human use.
-
Brief DescriptionBI-4020 is a fourth-generation, non-covalent, and orally active inhibitor of EGFR tyrosine kinase.
-
DescriptionBI-4020 is a fourth-generation, non-covalent, and orally active inhibitor of EGFR tyrosine kinase.(In Vitro):BI-4020 inhibits p-EGFR del19 T790M C797S ( IC50: 0.6 nM). BI-4020 inhibits not only the triple mutant EGFR (del19/T790M/C797S) variant (IC50=0.2 nM in BaF3 cell lines) but also the double mutant EGFR (del19/T790M) and primary mutant EGFR del19 (IC50: 1 nM). BI-4020 also shows activity against EGFR wt (IC50: 190 nM). BI-4020 shows high kinome selectivity and good DMPK properties.(In Vivo):In the human PC-9 (EGFR del19/T790M/C797S) triple mutant NSCLC xenograft model in mice, BI-4020 leads to tumor regressions.
-
Synonyms——
-
PathwayAngiogenesis
-
TargetEGFR
-
RecptorBacterial
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2664214-60-0
-
Formula Weight542.7
-
Molecular FormulaC30H38N8O2
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESO=C(C1=CC(C)=NC(C2=C(OCCC[C@@H](C)C3)N(C)N=C2)=C1)/N=C(N4)/N3C5=C4C=CC(CN6CCN(C)CC6)=C5
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.M K M Nair, et al. Antibacterial effect of caprylic acid and monocaprylin on major bacterial mastitis pathogens. J Dairy Sci. 2005 Oct;88(10):3488-95.
molnova catalog
related products
-
Varlitinib
Varlitinib is a selective and potent ErbB1(EGFR) and ErbB2(HER2) inhibitor with IC50 of 7 nM and 2 nM respectively. Phase 2.
-
AG 99
AG-99 is an inhibitor of EGFR kinase (IC50: 10 μM in the human epidermoid carcinoma cell line A431).
-
Dacomitinib
Dacomitinib (PF-00299804, PF-299804) is a potent, irreversible, orally active pan-ErbB receptor tyrosine kinase inhibitor with IC50 of 6, 45.7 and 73.7 for EGFR, ERBB2 and ERBB4, respectively.
